CF
MDGL icon

Centaurus Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Centaurus Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$371K Hold
709
– – 0.02% 611
2025
Q4 		$413K Hold
709
– – 0.02% 574
2025
Q3 		$325K Buy
709
+34
+5% +$12.7K 0.02% 654
2025
Q2 		$204K Sell
675
-15
-2% -$4.47K 0.01% 717
2025
Q1 		$229K Hold
690
– – 0.01% 643
2024
Q4 		$213K Buy
690
+79
+13% +$22.2K 0.01% 646
2024
Q3 		$130K Buy
611
+28
+5% +$7.16K 0.01% 770
2024
Q2 		$163K Buy
+583
New +$139K 0.01% 657

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Centaurus Financial's MDGL Position: Q1 2026 in Review

Centaurus Financial held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2026 at 709 shares worth $371K. The position accounts for 0.02% of the portfolio, ranked #611.

Centaurus Financial first reported a position in MDGL in Q2 2024 and has held it in 8 quarters since. The position peaked at $413K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Centaurus Financial held 709 shares of Madrigal Pharmaceuticals worth $371K as of Q1 2026.
  • Centaurus Financial left its Madrigal Pharmaceuticals share count unchanged in Q1 2026.
  • Madrigal Pharmaceuticals made up 0.02% of Centaurus Financial's portfolio in Q1 2026, its #611 holding.
  • Centaurus Financial first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Centaurus Financial's Madrigal Pharmaceuticals position peaked at $413K in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.